share_log

Here's Why We Think Afya (NASDAQ:AFYA) Is Well Worth Watching

Here's Why We Think Afya (NASDAQ:AFYA) Is Well Worth Watching

這就是爲什麼我們認爲Afya(納斯達克: AFYA)值得關注
Simply Wall St ·  12/02 19:44

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. But the reality is that when a company loses money each year, for long enough, its investors will usually take their share of those losses. Loss-making companies are always racing against time to reach financial sustainability, so investors in these companies may be taking on more risk than they should.

對於新手來說,買入一家向投資者講述良好故事的公司,即使當前缺乏收入和盈利記錄,可能聽起來是個好主意(令人興奮的前景)。但現實情況是,當一家公司每年都虧損足夠長的時間時,它的投資者通常會承擔這些損失的份額。赤字企業始終在爭分奪秒地追求財務可持續性,因此這些企業的投資者可能承擔了更多的風險。

So if this idea of high risk and high reward doesn't suit, you might be more interested in profitable, growing companies, like Afya (NASDAQ:AFYA). Now this is not to say that the company presents the best investment opportunity around, but profitability is a key component to success in business.

因此,如果這種高風險高回報的理念不適合您,您可能對像Afya(納斯達克:AFYA)這樣的盈利且增長的公司更感興趣。這並不是說該公司提供了最佳的投資機會,但盈利能力是業務成功的關鍵要素。

How Quickly Is Afya Increasing Earnings Per Share?

Afya每股收益增長的速度有多快?

If you believe that markets are even vaguely efficient, then over the long term you'd expect a company's share price to follow its earnings per share (EPS) outcomes. So it makes sense that experienced investors pay close attention to company EPS when undertaking investment research. Impressively, Afya has grown EPS by 37% per year, compound, in the last three years. If the company can sustain that sort of growth, we'd expect shareholders to come away satisfied.

如果您認爲市場即使在某種程度上是有效的,那麼從長期來看,您會期望一家公司股票的價格跟隨其每股收益(EPS)的結果。因此,經驗豐富的投資者在進行投資研究時密切關注公司EPS是有道理的。令人印象深刻的是,Afya在過去三年中每股收益複合增長了37%。如果該公司能夠維持這種增長,我們預計股東會感到滿意。

One way to double-check a company's growth is to look at how its revenue, and earnings before interest and tax (EBIT) margins are changing. The music to the ears of Afya shareholders is that EBIT margins have grown from 27% to 29% in the last 12 months and revenues are on an upwards trend as well. Both of which are great metrics to check off for potential growth.

檢查公司增長的一種方法是查看其營業收入以及息稅前利潤(EBIT)利潤率的變化。對Afya股東來說好消息是,EBIT利潤率在過去12個月中從27%增長到29%,營業收入也在持續上升。這兩者都是檢查潛在增長的良好指標。

The chart below shows how the company's bottom and top lines have progressed over time. Click on the chart to see the exact numbers.

下面的表格顯示了公司的營收和淨利潤如何隨着時間的推移的變化。點擊圖表可以查看準確的數字。

big
NasdaqGS:AFYA Earnings and Revenue History December 2nd 2024
納斯達克上市公司:AFYA 收益與營業收入歷史 2024年12月2日

You don't drive with your eyes on the rear-view mirror, so you might be more interested in this free report showing analyst forecasts for Afya's future profits.

你不會在開車時盯着後視鏡,因此你可能會更感興趣於這份免費報告,其中展示了分析師對Afya未來利潤的預測。

Are Afya Insiders Aligned With All Shareholders?

Afya的內部人士是否與所有股東保持一致?

It should give investors a sense of security owning shares in a company if insiders also own shares, creating a close alignment their interests. Shareholders will be pleased by the fact that insiders own Afya shares worth a considerable sum. Indeed, they have a considerable amount of wealth invested in it, currently valued at R$386m. This totals to 26% of shares in the company. Enough to lead management's decision making process down a path that brings the most benefit to shareholders. So there is opportunity here to invest in a company whose management have tangible incentives to deliver.

如果內部人士也擁有公司的股份,這應該會給投資者一種持有該公司股票的安全感,從而使他們的利益保持緊密一致。股東們會因爲內部人士持有價值可觀的Afya股份而感到高興。實際上,他們在該公司投資了大量財富,目前估值爲R$38600萬。這佔公司股份的26%。足以引導管理層的決策過程走上最有利於股東的道路。因此,這裏有機會投資於一家管理層擁有實質性激勵的公司。

Does Afya Deserve A Spot On Your Watchlist?

Afya值得在你的自選中佔有一席之地嗎?

You can't deny that Afya has grown its earnings per share at a very impressive rate. That's attractive. This EPS growth rate is something the company should be proud of, and so it's no surprise that insiders are holding on to a considerable chunk of shares. Fast growth and confident insiders should be enough to warrant further research, so it would seem that it's a good stock to follow. Now, you could try to make up your mind on Afya by focusing on just these factors, or you could also consider how its price-to-earnings ratio compares to other companies in its industry.

你無法否認Afya每股收益以非常令人印象深刻的速度增長。這是非常有吸引力的。這個每股收益的增長率是公司應該引以爲豪的,因此內部人士持有相當一部分股票也就不足爲奇了。快速增長和自信的內部人士應該足以促使進一步研究,因此看起來這是一個值得關注的股票。現在,你可以試着僅僅關注這些因素來決定是否投資Afya,或者你也可以考慮它的市盈率與行業內其他公司的比較。

While opting for stocks without growing earnings and absent insider buying can yield results, for investors valuing these key metrics, here is a carefully selected list of companies in the US with promising growth potential and insider confidence.

儘管不增長收益且沒有內部人士購買的股票可能會有回報,但對於重視這些關鍵指標的投資者來說,以下是在美國具有潛在增長和內部人士信心的經過慎重篩選的公司列表。

Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.

請注意,本文討論的內部交易是指在相關司法管轄區中報告的交易。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論